Earnings call transcripts

Management framed Q2 as accelerating adoption across plaque and FFRCT, with stronger confidence supporting a higher outlook and longer-term asymptomatic expansion plans.

Management framed Q2 as evidence that pricing, product mix and a lean digital model are improving profitability while Pee Logistics opens a second growth path.

Management framed the Proteus delay as a deliberate de-risking decision, prioritizing manufacturing repeatability and launch readiness over the prior timeline.

Management framed Q2 as evidence that cost actions are entering the run rate, while recurring growth and second-half execution remain central to profitability plans.

Management framed the quarter as an inflection toward growth, driven by delayed launches, expanding SafePath channels and a stronger pipeline.

The new CEO framed the quarter as a strategic reset toward provider-led growth, sharply lower spending, and a longer-term CSU opportunity.

Management framed the quarter as a financing-related timing setback against improving commercial momentum, with execution and pipeline conversion now central to a stronger second half.

Management framed the call around accountability: cost structure improved, but slower ShotSpotter sales and delayed deployments forced a sharp revenue reset.

Management framed the call around regulatory progress and assembling a U.S. supply chain, while acknowledging slower permitting and unresolved funding.

Management framed AI, self-contained see-through glasses and waveguide manufacturing as converging catalysts for a commercialization inflection.

Management framed the quarter as evidence of stabilization and cost discipline, while emphasizing technology upgrades, new customer channels, and strategic flexibility.

Management shifted the regulatory story from cardiomyopathy toward a potential upper-limb indication, while emphasizing uncertainty around FDA timing and containing spending.